NCT05683873RecruitingNot Applicable
Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package
Centre Hospitalier Universitaire Dijon2 sites in 1 country130 target enrollmentStarted: February 13, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 130
- Locations
- 2
- Primary Endpoint
- Global Longitudinal Strain (GLS) of the left ventricle measured by trans-thoracic ultrasound (TTE)
Study Overview
Brief Summary
The aim of this study is to analyze the relationship between the blood biomarker GDF-15 and heart damage after stroke.
It is being conducted in France, in the Neurology Department of the Dijon University Hospital (Burgundy). The research is interventional because a biological blood test will be performed, as well as a heart rhythm recording and several cardiac echograms during the hospitalization of the participants and during the follow-up consultation scheduled 4 to 6 months after the stroke.
A total of 130 stroke patients will participate in this study.
Participation includes 4 visits:
- Inclusion visit (within 24 hours of the first stroke symptoms)
- visit 1 (within 24 to 72 hours of stroke)
- visit 2 (within 48 hours of visit 1)
- Visit 3 (approximately 4-6 months post-stroke)
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral MRI)
- •Whose first symptoms appeared within 24 hours before inclusion
- •Whose consent to participate in this study was obtained from the patient or a close relative.
Exclusion Criteria
- •Person with a history of symptomatic stroke, either ischemic or hemorrhagic
- •Anyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure, pacemaker, defibrillator, or other cardiac devices
- •Person with acute heart failure, suspected infective endocarditis, STEMI, or concurrent pulmonary embolism
- •A person who is not a member or beneficiary of a social security system
- •Person deprived of liberty
- •Person subject to a legal protection measure (curatorship, guardianship)
- •Person subject to a legal protection measure
- •Pregnant, parturient or breastfeeding woman
Outcomes
Primary Outcomes
Global Longitudinal Strain (GLS) of the left ventricle measured by trans-thoracic ultrasound (TTE)
Time Frame: within 24 to 72 hours post-stroke
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Not yet recruiting
Unknown
The ASPIRE Trial - understanding the impact of mucositis on cachexia in head and neck cancerhead and neck cancermucositiscachexiaCancer - Head and neckInflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonMusculoskeletal - Other muscular and skeletal disordersACTRN12623000521628niversity of Adelaide25
Completed
Not Applicable
Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.Polycystic Ovary SyndromeNCT01644305Ankara Education and Research Hospital85
Active, not recruiting
Not Applicable
GDF-15 levels as prognostic marker in patients with Atrial FibrillatioGrowth and differentiation Factor-15C14.280.067.198RBR-106xbn9sniversidade Federal Fluminense
Completed
Not Applicable
GDF-15 Levels in Risk Stratification in Acute Pulmonary EmbolismPulmonary EmbolismNCT03672123Medical University of Warsaw270
Completed
Not Applicable
Research for myocardial viability by using 18F-FDG PET/MRIOld myocardial infarctionJPRN-UMIN000021351Fukushima Medical University100